Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV002242820 | SCV001582998 | pathogenic | Osteogenesis imperfecta type I; Ehlers-Danlos syndrome, classic type, 1 | 2020-06-01 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Glycine residues within the Gly-Xaa-Yaa repeats of the triple helix domain are required for the structure and stability of fibrillar collagens (PMID: 7695699, 8218237, 19344236). In COL1A2, variants affecting these glycine residues are significantly enriched in individuals with disease (PMID: 9016532, 17078022) compared to the general population (ExAC). This variant has been observed in individual(s) with autosomal dominant osteogenesis imperfecta types III and IV (PMID: 11317364, 29620724). This variant is also known as G184D in the literature. This variant is not present in population databases (ExAC no frequency). This sequence change replaces glycine with aspartic acid at codon 274 of the COL1A2 protein (p.Gly274Asp). The glycine residue is highly conserved and there is a moderate physicochemical difference between glycine and aspartic acid. |